Hindi nagbibigay ng serbisyo ang XM sa mga residente ng Estados Unidos.

Hindi nagbibigay ng serbisyo ang XM sa mga residente ng Estados Unidos.
F
F

Fresenius

Balita

Reuters - 18 oras ang nakaraan

FDA Says Fresenius Kabi USA Removes Certain Ivenix Large Volume Pump Primary Administration Sets

BRIEF-FDA Says Fresenius Kabi USA Removes Certain Ivenix Large Volume Pump Primary Administration Sets Sept 16 (Reuters) - FDA: FDA: INFUSION PUMP ADMINISTRATION SET RECALL, FRESENIUS KABI USA REMOVES CERTAIN IVENIX LARGE VOLUME PUMP PRIMARY ADMINISTRATION SETS FDA: FDA IDENTIFIED FRESENIUS KABI USA'S CERTAIN IVENIX LARGE VOLUME PUMP PRIMARY ADMINI
F
Reuters - 4 araw ang nakaraan

Top of the Street: Roche, Fresenius, BASF, AstraZeneca, Rational, PSP Swiss Property, Swiss Prime Site

BUZZ-Top of the Street: Roche, Fresenius, BASF, AstraZeneca, Rational, PSP Swiss Property, Swiss Prime Site A round-up of notable broker activity this morning from Europe's top-ranked* analysts: ** Deutsche Bank cuts Roche ROG.S to "sell" from "buy", citing limited catalyst due to a risk of Roche creating a lot of sunk cost for little ultimate return ** J.P.Morgan upgrades Fresenius FREG.DE to "overweight" from "neutral" as it sees earnings compression at the German healthcare group coming to an
A
B
F
J
R
R
S
P
F
Reuters - 4 araw ang nakaraan

Alstom, Siemens, Tesco

EUROPE RESEARCH ROUNDUP-Alstom, Siemens, Tesco Sept 13 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Alstom, Siemens and Tesco, on Friday. HIGHLIGHTS * Alstom ALSO.PA : HSBC raises target price to EUR 26 from EUR 24 * Hexagon AB HEXAB.ST : HSBC cuts target price to SEK 110 from SEK 120 * Siemens AG SIEGN.DE : HSBC cuts target price to EUR 140 from EUR 150 * Tesco TSCO.L : Citigroup raises target price to 425p from 350p * Travis P
A
A
A
B
B
B
C
C
C
D
D
E
E
F
H
H
I
K
L
L
S
S
S
S
T
T
P
A
A
F
S
U
Reuters - 4 araw ang nakaraan

'Medicine is starting to work', JPM upgrades Fresenius

BUZZ-'Medicine is starting to work', JPM upgrades Fresenius ** J.P.Morgan upgrades Fresenius FREG.DE to "overweight" from "neutral" as it sees earnings compression at the German healthcare group coming to an end ** The broker says Fresenius delivered results above expectations in each of the last four quarters and management made progress in improv
F
F
Reuters - 2 linggo ang nakaraan

Fresenius Divests IV Manufacturing Site In Chile

BRIEF-Fresenius Divests IV Manufacturing Site In Chile Sept 2 (Reuters) - FRESENIUS SE & CO KGAA FREG.DE : DIVESTS IV MANUFACTURING SITE IN CHILE THIS DIVESTMENT INCLUDES IV LABORATORIO SANDERSON PLANT IN SANTIAGO DE CHILE WILL CONTINUE MANUFACTURING OF EXISTING PORTFOLIO OF PRODUCTS IN CHILE FRESENIUS KABI REMAINS COMMITTED TO CHILEAN AS WELL AS S
F
Reuters - 1 buwan ang nakaraan

Adyen NV, Beazley, Nel ASA

EUROPE RESEARCH ROUNDUP-Adyen NV, Beazley, Nel ASA Aug 16 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Adyen NV, Beazley and Nel ASA, on Friday. HIGHLIGHTS * Adyen NV ADYEN.AS : TD Cowen raises target price to EUR 1,620 from EUR 1,618 * Beazley BEZG.L : HSBC raises target price to 780p from 665p * Diageo DGE.L : HSBC cuts target price to 3,000p from 3,300p * Nel ASA NEL.OL : Berenberg cuts to hold from buy * ThyssenKrupp Nucera
A
A
B
B
B
C
C
D
D
E
F
F
G
H
I
L
P
P
S
T
V
D
D
F
Reuters - 2 buwan ang nakaraan

Danske Bank, Greggs, HSBC

EUROPE RESEARCH ROUNDUP-Danske Bank, Greggs, HSBC Aug 1 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Danske Bank, Greggs, and HSBC, on Thursday. HIGHLIGHTS * Danske Bank DANSKE.CO : HSBC raises target price to DKK 258 from DKK 257 * Greggs GRG.L : Berenberg raises target price to 3600p from 3340p * HSBC HSBA.L : Berenberg raises target price to 870p from 830p * Kardex Holding AG KARN.S : Berenberg raises target price to CHF 260
A
A
A
A
A
B
B
C
C
C
D
F
G
G
H
L
T
W
A
D
S
Reuters - 2 buwan ang nakaraan

Fresenius beats Q2 view on strong unit performance, cost savings

UPDATE 2-Fresenius beats Q2 view on strong unit performance, cost savings Adds details on restructuring in paragraphs 5, 6, profit for units in paragraph 7 By Bartosz Dabrowski July 31 (Reuters) - German healthcare group Fresenius FREG.DE beat second-quarter operating profit expectations on Wednesday, citing strong performance at its Kabi and Helios units, and progress in group-wide cost savings.
F
F
Reuters - 2 buwan ang nakaraan

Fresenius beats Q2 expectations on strong unit performance, cost savings

Fresenius beats Q2 expectations on strong unit performance, cost savings July 31 (Reuters) - German healthcare group Fresenius FREG.DE beat second-quarter operating profit expectations on Wednesday, citing strong performance at its Kabi and Helios units, and progress in group-wide cost savings. It reported earnings before interests and taxes (EBIT) of 660 million euros ($714 million), up 16% from a year ago.
F
F
Reuters - 2 buwan ang nakaraan

Dialysis firm FMC cuts outlook for US treatment volumes, shares fall

UPDATE 1-Dialysis firm FMC cuts outlook for US treatment volumes, shares fall Recasts with US patient volumes outlook, adds shares in paragraph 4 July 30 (Reuters) - World's largest dialysis specialist Fresenius Medical Care FMEG.DE cut the outlook for volumes in its key U.S. market on Tuesday after revenue from treatments there fell in the second quarter, weighed down by elevated mortality due to COVID-19 and flu among its patients.
F
F
Reuters - 2 buwan ang nakaraan

Dialysis specialist FMC's Q2 profit meets expectations

Dialysis specialist FMC's Q2 profit meets expectations July 30 (Reuters) - World's largest dialysis specialist Fresenius Medical Care FMEG.DE reported adjusted second-quarter operating profit in line with expectations on Tuesday. Robust earnings in its health care products division, which produces dialysis machines, helped offset weaker patient volumes in the main health care services division, which provides dialysis procedures.
F
F
Reuters - 2 buwan ang nakaraan

Germany corporate earnings week ahead

DIARY-Germany corporate earnings week ahead July 26 (Reuters) - Diary of Germany (.GDAXI) corporate earnings for the week ahead GERMANY EARNINGS Start Date Start Time (GMT) RIC Company Name Event Name 30-Jul-2024 NTS 1COV.DE Covestro AG Half Year 2024 Covestro AG Earnings Release 30-Jul-2024 BMO HEIG.DE Heidelberg Materials AG Half Year 2024 Heidelberg Materials AG Earnings Release 30-Jul-2024 04:30 AIR.PA Airbus SE Half Year 2024 Airbus SE Earnings Release 31-Jul-2024 AMC QGEN.N Qiagen NV Q2 20
A
A
B
F
M
P
S
S
V
V
Q
G
Reuters - 2 buwan ang nakaraan

MS raises Fresenius to 'overweight' on 'tipping point on portfolio simplification'

BUZZ-MS raises Fresenius to 'overweight' on 'tipping point on portfolio simplification' ** Morgan Stanley raises Fresenius FREG.DE to "overweight" from "equal weight," as it sees the German healthcare group has "reached a tipping point on portfolio simplification" ** The analyst says that Kabi, the company's division for IV drugs, nutrition product
F
F
Reuters - 2 buwan ang nakaraan

Anglo American, Rio Tinto, Unilever

EUROPE RESEARCH ROUNDUP-Anglo American, Rio Tinto, Unilever July 23 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Anglo American, Rio Tinto and Unilever, on Tuesday. HIGHLIGHTS * Anglo American Plc AAL.L : HSBC cuts target price to 2,300p from 2,450p * Antofagasta Plc ANTO.L : HSBC raises target price to 1,400p from 1,100p * Belimo Holding AG BEAN.S : Jefferies raises target price to CHF 598 from CHF 498 * Rio Tinto RIO.L : HSBC
A
A
A
B
B
D
E
F
G
G
G
P
T
W
A
A
B
G
R
Reuters - 2 buwan ang nakaraan

Fresenius SE: Announces EMA Acceptance For Review Of Denosumab Biosimilar Candidates

BRIEF-Fresenius SE: Announces EMA Acceptance For Review Of Denosumab Biosimilar Candidates July 11 (Reuters) - Fresenius SE & Co KGaA FREG.DE : ANNOUNCES EMA ACCEPTANCE FOR REVIEW OF DENOSUMAB BIOSIMILAR CANDIDATES Further company coverage: FREG.DE Reporting by Berlin Newsroom
F

Kundisyon

Mga Patok na Assets

Disclaimer: Ang mga kabilang sa XM Group ay nagbibigay lang ng serbisyo sa pagpapatupad at pag-access sa aming Online Trading Facility, kung saan pinapahintulutan nito ang pagtingin at/o paggamit sa nilalaman na makikita sa website o sa pamamagitan nito, at walang layuning palitan o palawigin ito, at hindi din ito papalitan o papalawigin. Ang naturang pag-access at paggamit ay palaging alinsunod sa: (i) Mga Tuntunin at Kundisyon; (ii) Mga Babala sa Risk; at (iii) Kabuuang Disclaimer. Kaya naman ang naturang nilalaman ay ituturing na pangkalahatang impormasyon lamang. Mangyaring isaalang-alang na ang mga nilalaman ng aming Online Trading Facility ay hindi paglikom, o alok, para magsagawa ng anumang transaksyon sa mga pinansyal na market. Ang pag-trade sa alinmang pinansyal na market ay nagtataglay ng mataas na lebel ng risk sa iyong kapital.

Lahat ng materyales na nakalathala sa aming Online Trading Facility ay nakalaan para sa layuning edukasyonal/pang-impormasyon lamang at hindi naglalaman – at hindi dapat ituring bilang naglalaman – ng payo at rekomendasyon na pangpinansyal, tungkol sa buwis sa pag-i-invest, o pang-trade, o tala ng aming presyo sa pag-trade, o alok para sa, o paglikom ng, transaksyon sa alinmang pinansyal na instrument o hindi ginustong pinansyal na promosyon.

Sa anumang nilalaman na galing sa ikatlong partido, pati na ang mga nilalaman na inihanda ng XM, ang mga naturang opinyon, balita, pananaliksik, pag-analisa, presyo, ibang impormasyon o link sa ibang mga site na makikita sa website na ito ay ibibigay tulad ng nandoon, bilang pangkalahatang komentaryo sa market at hindi ito nagtataglay ng payo sa pag-i-invest. Kung ang alinmang nilalaman nito ay itinuring bilang pananaliksik sa pag-i-invest, kailangan mong isaalang-alang at tanggapin na hindi ito inilaan at inihanda alinsunod sa mga legal na pangangailangan na idinisenyo para maisulong ang pagsasarili ng pananaliksik sa pag-i-invest, at dahil dito ituturing ito na komunikasyon sa marketing sa ilalim ng mga kaugnay na batas at regulasyon. Mangyaring siguruhin na nabasa at naintindihan mo ang aming Notipikasyon sa Hindi Independyenteng Pananaliksik sa Pag-i-invest at Babala sa Risk na may kinalaman sa impormasyong nakalagay sa itaas, na maa-access dito.

Babala sa Risk: Maaaring malugi ang iyong kapital. Maaaring hindi nababagay sa lahat ang mga produktong naka-leverage. Mangyaring isaalang-alang ang aming Pahayag sa Risk.